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Sulfation   
 Sulfation (sulfoconjugation or sulfonation) is one of the reactions in phase II drug 
metabolism targeting a broad range of xenobiotics and endogenous substrates, including 
drugs, toxic chemicals, steroid hormones, and neurotransmitters (Nimmagadda, Cherala, 
& Ghatta, 2006). This process is catalyzed by a supergene family of enzymes called 
sulfotransferases (SULTs), which transfer the sulfuryl group from the ubiquitous donor 
3'-phosphoadenosine 5'-phosphosulfate (PAPS) to a hydroxyl-containing or amine-
containing group of an acceptor molecule. Two classes of SULTs have been identified: 
membrane-bound SULTs and cytosolic SULTs. Membrane-bound SULTs are located on 
the Golgi apparatus of the cell and specifically sulfate peptides, proteins, lip d  and 
glycosaminoglycans (Chapman, Best, Hanson, & Wong, 2004; Falany, 1997; Negishi et 
al., 2001); cytosolic SULTs are responsible for the sulfation of xenobiotics and small 




to as cytosolic SULTs. In intact cells, the sulfation reaction may be reversed by sulfatases 
which exist in the endoplasmic reticulum (Nimmagadda et al., 2006; Kauffman, 2004). 
Sulfation plays a key role in a cell's defensive response against xenobiotics and may have 
a major function during early development since high SULT expression has been 
observed  in the human fetus (Kauffman, 2004). In most cases, this process is considered 
to be the detoxification pathway of numerous toxic xenobiotics, because by adding a 
sulfuryl group on the substrate compound, SULTs increase its water solubility and lead it 
to be readily excreted from the cell. However, many SULTs are also c pable of 
bioactivating procarcinogens, such as certain dietary and environmental agents, to 
reactive electrophiles. These electrophiles may covalently bind with DNA and proteins 
and cause damage to the cell (Glatt et al., 2001). Another major function of SULTs is 
regulating endocrine status. Sulfation occurs commonly in steroid biosynthesis, the 
metabolism of catecholamines and iodothyronines as well as the modification of estrogen 
and androgen receptors (Kauffman, 2004). The transfer reaction of the sulfuryl gro p of 
PAPS to the hydroxyl group of a steroid produces a steroid sulfate (Luu-The, Bernier, 
Dufort, & Labrie, 1996). This commonly-known detoxification reaction (sulfation) may 
play a role in steroid hormone synthesis since a steroid sulfate is the precurso  of most of 
the steroid hormones (Luu-The et al., 1996). Though the structures and functions of many 
SULT isoforms were identified years ago, the regulatory mechanism of human SULTs 






Isoforms, substrate specificity and tissue distribution   
 SULTs have a wide range of tissue distribution, but isoform expression varies 
between tissue types. Based on sequence analysis, SULTs have been divided into six 
families (Pacifici & Coughtrie, 2005). For humans, thirteen SULT isoforms have been 
identified so far, representing three families: SULT1, SULT2 and SULT4 (Gamage et al., 
2006). The SULT1 family, which comprises three SULT subfamilies (SULT1A, 
SULT1B, and SULT1C) (Freimuth et al., 2000; Fujita, Nagata, Ozawa, Sasano, & 
Yamazoe, 1997; Weinshilboum et al., 1997), has eight members and typically catalyzes 
transfer of a sulfuryl group to the hydroxyl group of a phenolic substrate (Pacifici & 
Coughtrie, 2005). The SULT2 family has two subfamilies (SULT2A and SULT2B) and 
contains the SULTs specific for the sulfation of hydroxylsteriod. The SULT4 family is 
least studied family of SULTs so far, and no specific substrate is currently known for this 
family of enzymes. All that is known about this family is that SULT4A1 is of highly 
expressed in the brain (Gamage et al., 2006). The gene location, distribution and 
substrate specificity of human cytosolic SULTs are listed in Table 1. The liver expresses 
most of the SULT isoforms because it is the main detoxification organ in the body. The 
SULT1 family is expressed mainly in detoxification organs, indicating that their main 
function is detoxification, specifically detoxifying phenolic xenobiotics. TheSULT2 
family is expressed in endocrine glands as well as the target organs of endocrine 
hormones, such as the adrenal gland and the liver. SULT2 enzymes are reportd to be 
involved in the regulation of cellular hormone systems  (Chen, Chen, Head, Mangelsdorf, 
















minoxidil,E2, E1, DES, 4-
hydroxytamoxifen, naringenin, 
genistein, dopamine, epinephrine; 
numerous monocyclic phenols; 
iodothyronines; 2-naphthol, OH-PhIP 







No site found 
SULT1A3 16p11.2 
Dopamine, norepinephrine, 
isoprenaline, 2-hydroxy-E2 and other 
catechols, numerous monocyclic 
phenols; vanillin, 1-naphthol; 
albuterol and various other β2 
agonists; dopamine> tyramine> p-
nitrocatechol, m-nitrocatechol, 4-
nitrophenol, p-cresol, 4-aminophenol, 
4-ethylphenol; E1; minoxidil 
Adult gastrointestinal 
tract, adult platelets, 
adult brain, placenta, 
fetal liver 
SULT1B1 4q11-13 
1-Naphthol> 4-nitrophenol> DES, 
iodothyronines 
Adult liver, adult and 
fetal gastrointestinal 
tract 
SULT1C2 2q11.2 4-Nitrophenol> OH-AAF 
Fetal kidney, lung, 
and gastrointestinal 
tract 
SULT1C4 2q11.2 No substrate known Fetal kidney and lung 
SULT1E1 4q13 
E2, E1, pregnenolone, 17-ethinyl-E2, 
equilenin; DHEA, 1-naphthol, DES, 4-
hydroxytamoxifen, narigenin, 
genistein; iodothyronines; minoxidil 
Fetal liver, lung, and 




androsterone> testosterone> E2; 
cholesterol; lithocholic acid and 
various other bile acids; 
pregnenolone> 17-ethinyl-E2> 
cortisol; minoxidil 
Fetal and adult 
adrenal gland and 
liver 
SULT2B1 19q13.3 DHEA 
Adult skin, prostate, 
and placenta 
SULT4A1 22q13.1-13.2 No substrate known Brain 
Abbreviations: DHEA, dehydroepiandrosterone; E2, 17β-estradiol; E1, estrone; OH-PhIP, N-hydroxy-2-amino-1-
methyl-6-phenylimidazo pyridine; DES, diethylstilbestrol; OH-AAF, N-hydoxy-2-acetylaminofluorene. 




Sulfotransferase 1A1   
 Sulfotransferase 1A1 (SULT1A1) belongs to the SULT1A subfamily, and is also 
known as the "simple phenol SULT". Human SULT1A1 is the most commonly-studied 
SULT. It is responsible for the sulfation of phenolic drugs, such as acetaminophen, 
minoxidil, 17α-ethinylestradiol, etc. (Pacifici & Coughtrie, 2005). SULT1A1 also 
sulfates endogenous compounds, such as 17β-estradiol and iodothyronines, as well as 
environmental xenobiotics, such as the isoflavones (Pacifici & Coughtrie, 2005). It is 
widely distributed in human body, showing high expression in the liver and expression to 
a lesser degree in brain, breast, intestine, endometrium, kidney, lung, and platelets 
(Falany & Falany, 1996; Falany, Azziz, & Falany, 1998). 
 
Sulfotransferase 1E1   
 Sulfotransferase 1E1 (SULT1E1) belongs to the SULT1E subfamily, which is 
also among the most widely studied of the SULT enzymes. The first SULT protein f r 
which a crystal structure was resolved was mouse SULT1E1 (Kakuta, Pedersen, Carter, 
Negishi, & Pedersen, 1997; Kakuta, Petrotchenko, Pedersen, & Negishi, 1998). SULT1E 
family members specifically sulfate 3α-hydroxyl groups of endogenous and xenobiotic 
estrogens with high affinity (Aksoy, Wood, & Weinshilboum, 1994; Coughtrie e  al., 
1994; Coughtrie, Sharp, Maxwell, & Innes, 1998; Falany, Wheeler, Oh, & Falany, 1994; 
Falany, 1997). SULT1E1 is observed to be expressed in some steroid-hormone-
responsive tissues, such as the adrenal gland, the testis as well as the placenta, dep ding 





Sulfotransferase 2A1   
 Sulfotransferase 2A1 (SULT2A1) belongs to the SULT2 family and is also 
known as the dehydroepiandrosterone (DHEA) SULT. SULT2A1 is the only SULT 
capable of sulfating DHEA, however, it can also sulfate a variety of other endogous 
compounds, such as pregnenolone, cholesterol, cortisol, benzylic alcohols of Polycyclic 
aromatic hydrocarbons (PAHs), testosterone and the bile salts (Pacifici, 2005). SULT2A1 
is the only member of the SULT2 family that is capable of catalyzing the sulfation of the 
phenolic hydroxy group at the 3 position of estrogens (Parker, Jr., Falany, Stockard, 
Stankovic, & Grizzle, 1994; Parker, Jr., Stankovic, Falany, Faye-Petersen, & Grizzle, 
1995). This DHEA SULT is localized mainly in the fetal zone and neocortex (Parker, J . 
et al., 1994; Parker, Jr. et al., 1995).  The crystal structure of human SULT2A1 has been 
resolved (Pedersen, Petrotchenko, & Negishi, 2000). 
 
Sulfotransferase 2B1   
 Sulfotransferase 2B1 (SULT2B1) belongs to the SULT2B subfamily and was 
recently detected in a variety of hormone-responsive tissues. The SULT2B1 gene 
encodes two SULT isoforms, SULT2B1a and SULT2B1b, resulting from different 
initiation sites of transcription or alternative mRNA splicing (Geese & Raftogianis, 2001; 
Kohjitani, Fuda, Hanyu, & Strott, 2006; Meloche & Falany, 2001; Koizumi et al., 2009; 
Her et al., 1998). According to the information of Gene Bank, SULT2B1a is fifteen 




acid at the amino-terminal (N') end of the protein. The final 344 amino acid of both 
sequences are the same because they are from the same exons on the original gene 
(Falany, He, Dumas, Frost, & Falany, 2006; Her et al., 1998; Kohjitani et al., 2006; 
Shimizu, Fuda, Yanai, & Strott, 2003). The SULT2B1b isoform specifically sulfonates 
cholesterol and cholesterol derivatives, whereas SULT2B1a is specific to pregnenolone. 
Recent studies indicate that SULT2B1b is responsible for the sulfation of oxysterols, 
which are cholesterol derivatives and known to have deleterious effects on biolgical 
processes (Fuda, Javitt, Mitamura, Ikegawa, & Strott, 2007). There is selective tissue 
expression of SULT2B1 isoforms in rats. The SULT2B1a isoform is known to be 
expressed only in the testis and brain of male rats, whereas the SULT2B1b isoform is 
expressed in most other tissues (Kohjitani et al., 2006; Kohjitani et al., 2006). Different 
from the other SULT isoforms, both SULT2B1 isoforms likely have little rolein 
xenobiotic detoxification. Although the regulatory mechanisms of these two isoforms still 
remain unclear, it has been shown that they are involved in regulating lipid and 




 The endocrine system is comprised of endocrine glands, the hormones they 
secrete, and the reaction these hormones produce. Like all other systems in the body, the 
endocrine system contains a variety of interacting parts. Endocrine glands are the body's 




or the ovary. They include the hypothalamus, the pituitary gland, the pineal gland, the 
thyroid and parathyroid glands, the adrenal gland, the thymus gland, and the testis/ovary. 
The hormones they secrete are distributed to the rest of the body through the bloodstream 
and interact with the target cells that receive their messages. Special proteins bind to 
hormones on their way to the target cells to control the amount of hormone available to 
interact with the target cells. The target cells receive the hormones by specific receptors 
on the cell membranes. The hormone levels in the blood are maintained by certain 
regulatory mechanisms. Excessive or insufficient hormone expression causes dysfunction 
within the body. The endocrine system controls body processes that happen slowly. Other 
faster body processes, like breathing or body movement, are controlled by the nervous 
system. The nervous system and the endocrine system work together to maintain normal 
body functions. Hormone levels can be influenced by environmental factors such as 
drugs, food components, stresses, diseases, etc. Hormones control biological processes 
through nuclear receptors at target tissues.  
 
Thyroid hormones   
 The thyroid gland is located in the front part of the lower neck and produces the 
thyroid hormones thyroxin (T4) and triiodothyronine (T3). These hormones are required 
for normal brain and somatic development and for the important regulation of 
physiological condition in the body (Zoeller, 2010). They are also involved in the 
circadian rhythms that govern sleep (Rieser & Kemp, 2010). T3 plays an important role in 




(Huang, Tsai, & Lin, 2008; Sprague, Mallett, Rusyniak, & Mills, 2004). As the level of 
thyroid hormones increase in the bloodstream, so does the speed at which chemical 
reactions occur in the body. Thyroid hormones also play a key role in bone growth and 
the development of the brain and nervous system in children (Rieser & Kemp, 2010). The 
production and release of thyroid hormones is dynamically controlled within a narrow 
range under normal conditions by the hypothalamus and the pituitary gland (Zoeller, 
2010). Many drugs and medications can alter thyroid hormone levels by affecting the 
hypothalamus, the thyrotropes (in the anterior pituitary), synthesis and secretion f om the 
thyroid gland, and metabolism of thyroid hormones through deiodination, sulfation and 
glucuronidation (Surks & Sievert, 1995; Haugen, 2009). Thyroid hormone levels can also 
be affected by drugs through altered affinity of thyroxin-binding globulin. Moreover, 
drugs can affect absorption of thyroid hormones or actions of thyroid hormones at the 
hormone target organs  (Haugen, 2009; de Groot, Zonnenberg, Plukker, van Der Graaf, & 
Links, 2005). Environmental chemicals affecting both thyroid hormone circulating level 
and thyroid hormone action in target tissues are considered to be thyroid toxican s 
(Zoeller, 2010). 
   
Adrenal hormones   
 The body has two triangular adrenal glands, one on the upper pole of each kidney, 
which are anatomically divided into two parts: a cortex and a medulla (Hardy & Cooper, 
2010). The adrenal cortex is the outer part of the adrenal gland that synthesizes adrenal 




balance in the body, the body's response to stress, metabolism, the immune system, and 
sexual development and function (Maggio & Segal, 2010). Steroid hormones are derived 
from the same precursor, cholesterol, through a complex series of biochemical r actions 
(Hardy & Cooper, 2010). Different steroid hormones have different specificities for 
steroid hormone receptors though they are all derived from the same precursor and have 
very similar structures (Hardy & Cooper, 2010). The inner part of the adrenal gla ds, the 
medulla, produces catecholamines, such as epinephrine, which is also called adrenaline. 
Epinephrine increases blood pressure and heart rate when the body experiences stresses, 
known as "fight or flight" responses (Rieser & Kemp, 2010).  
 
 
Sex hormones   
 Sex hormones are also known as sex steroids. They are steroid hormones that 
control the development and maintenance of sex characteristics by binding to vertebrat  
androgen or estrogen receptors (Guerriero, 2009). Their functions and effects are 
controlled either by slow, genomic mechanisms through nuclear receptors or by fast, non-
genomic mechanisms through signaling cascades (Thakur & Paramanik, 2009). The two 
main classes of sex hormones are androgens and estrogens, for male and female 
vertebrates, respectively. Androgens, also called testoids, include anabolic ster ids, 
androstenedione, dehydroepiandrosterone, dihydrotestosterone, and testosterone, 




sex characteristics. The female sex hormones, estrogens, are all derived from androgens 
and include estradiol, estriol, and estrone. 
 
Methamphetamine 
 The psychostimulant methamphetamine (METH) increases alertness and energy,
and in high doses, can induce euphoria, enhance self-esteem, and increase sexual pleasure 
(Mack, France, & Miller, 2005; Logan 2002). It was approved by the FDA to treat
attention deficit hyperactive disorder (ADHD), narcolepsy and exogenous obesity, under 
the trademark name Desoxyn®TM (Rxlist-Desoxyn, 2010). However, METH also has 
high potential for abuse and addiction by increasing the levels of dopamine, 
norepinephrine and serotonin in the brain's psychological reward system (Riddle, 
Fleckenstein, & Hanson, 2006). METH blocks dopamine reuptake by antagonizing the 
dopamine transporters on the membrane of the neuron cells and increases the dopamine 
level in the synapse, resulting in abnormally high levels of dopamine in the brain (Riddle 
et al., 2006). METH increases dopamine in the brain ten times more than the normal 
level, and this is four times more than elevation of dopamine by cocaine (Rawson, 2006). 
METH abuse has many critical consequences, such as anxiety, insomnia, mood 
disturbances and violent behavior. Long term abuse could even lead to death. A great 
deal of research has been conducted on METH during the past two decades. METH has 
been shown to not only affect central nervous system, but also affect the endocrine 
system in the body. Sprague et al. reported that T4 was strongly induced after high dose 




Banks, Cook, & Mills, 2003). METH injection also increases instant and chronic release 
of adrenal hormones, such as epinephrine (Grace, Schaefer, Gudelsky, Williams, & 
Vorhees, 2010; Williams, Schaefer, Furay, Ehrman, & Vorhees, 2006; Williams et al., 
2000; Schaefer et al., 2008).  
 
Hypotheses and Specific Aims  
 As stated previously, endocrine glands respond to METH by changing the level of 
secreted hormones. SULTs are involved in biosynthesis, regulation and metabolism of 
endocrine hormones. Both METH and SULTs are related to endocrine hormones, 
however, relatively little research has been conducted looking at the relationship between 
METH and SULTs. Only one report about METH's effect on SULTs was found in the 
literature. Dr. Kelsoe's group used microarray to identify a series of candidate genes 
whose expression is induced by METH treatment. They showed that the mRNA 
transcription of SULT1A1 was induced 4.3 times more than normal in the amygdala of 
rats 24 hours after METH treatment (Niculescu, III et al., 2000). The relationship 
between METH and body cytosolic SULTs has not been reported. The mechanisms of 
METH effects on SULTs also remain unclear.  
 Based on the above background information, we hypothesize that the expression 
of SULTs will be affected by METH in the adrenal gland, the thyroid gland, d the 
ovary/testis of rats. We are interested in studying the relationship between METH and the 




METH on mRNA transcription of different SULT isoforms in those three endocrine 
glands. To test our hypotheses, we developed the following specific aims: 
1. To investigate the effects of METH on protein expression of different SULT 
isoforms in the adrenal gland, the thyroid gland, and the ovary/testis of rats.   
2. To investigate the effects of METH on the mRNA transcriptions of different 
SULT isoforms in the adrenal gland, the thyroid gland, and the ovary/testis of 
rats. 
3. To investigate the effects of METH on protein expression and mRNA 
transcription of SULTs in the liver of rats (the liver is the main detoxificaton 










Methamphetamine was purchased from Sigma-Aldrich (St. Louis, MO). Sodium 
dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) reagents w re 
purchased from Bio-Rad (Hercules, CA). Fisher BioReagents* EZ-Run* Prestain d Rec 
Protein Ladder was purchased from Fisher Scientific (Pittsburgh, PA). Western blotting 
chemiluminescence reagent kits (Super Signal West Pico Stable Peroxide and Super 
Signal West Pico Luminol/Enhancer solutions) were purchased from Pierce Chemical 
(Rockford, IL). Nitrocellulose membranes (Immobilon-P; Millipore Corporatin, 
Bedford, MA) used for Western blots were purchased from Fisher Scientific (Fair Lawn, 
NJ). Protein assay reagent was obtained from Bio-Rad (Hercules, CA). Total RNA 
extraction kit (TRIZOL reagent) was purchased from Molecular Research Center, Inc. 
(Cincinnati, OH). GoScript™ Reverse Transcription System was purchased from 
Progema Corporation (Madison, WI). Real-time PCR Kits (qPCR MasterMix Plus for 
SYBR Green I dNTP) were purchased from EUROGENTEC (San Diego, CA). All other 





Animals and Drug Treatment 
 All procedures within this study were carried out with protocols approved by 
Oklahoma State University Animal Care and Use Committee.  
 Male and Female Sprague-Dawley rats (Harlan, Indianapolis, IN), 10 to 1 weeks 
old and 200-300 g body weight were used in this investigation. Rats were housed in a 
temperature- and humidity-controlled room and supplied with rodent chow and water for 
at least 1 week before use. Rats were divided randomly into groups of four. 
Methamphetamine was dissolved in saline and administrated by intraperitoneal injection 
at 1, 5 and 20 mg/kg to 3 separate groups of rats. The control rats received only thesa ine 
vehicle. The treatment was single dose treatment. The rats were euthanized 24 h after the 
drug treatment. The livers, the thyroid glands, the adrenal glands, and the testes/ovaries 
were collected from each rat and were snap-frozen in liquid nitrogen. Samples were 
stored at -80 ℃ until use.  
 
Cytosol Preparation 
 The liver, the thyroid gland, the adrenal gland, and the testis/ovary tissues were 
homogenized in 50 mM Tris buffer containing 0.25 M sucrose, 3 mM β-mercaptoethanol 
and 0.02% (v/v) Tween-20, pH 7.4. All homogenates were centrifuged at 100,000 x g for 
1h at 4 ℃. Cytosol aliquots were collected and the concentrations of protein were tested 
using Bio-Rad Protein Assay Dye Reagent Concentrate (Bio-Rad, Hercules, CA) on 




Brea, CA) according to manufacturer's protocol. The cytosol aliquots were then preserved 
at -80 ℃ for Western blotting analysis.  
 
Western Blot Analysis 
 The primary antibodies against rat sulfotransferases rSULT2A1 and rSULT1A1 
were provided by Dr. Michael W. Duffel (Division of Medicinal and Natural Products 
Chemistry, College of Pharmacy, The University of Iowa, Iowa city, IA). The primary 
antibody against rSULT1E1 was purchased from Biovision, Inc. (Boston, MA). The 
primary antibody against rSULT2B1a and rSULT2B1b (sc-t7103) was purchased from 
Santa Cruz Biotechnology, Inc. (Santa Cruz, CA).  
 Briefly, 15 µg cytosol protein from tissue of the liver, the thyroid gland, the 
adrenal gland or the testis/ovary was separated by electrophoresis (Bio-Rad, Hercules, 
CA) using 12% SDS polyacrylamide gel. After running 20 minutes at 90V (stacking gel) 
and 1 hour at 140V (separating gel), the protein bands were transferred overnight at 35 V 
onto a Polyvinylidene Fluoride (PVDF) nitrocellulose membrane at 4 ℃. Membranes 
were blocked for 1h with 5% (w/v) nonfat dry milk in Tris-buffered saline (TBST). For 
all the above-mentioned cytosol proteins, membranes were incubated with one of the 
following primary antibodies: goat anti-rat AST-IV (rSULT1A1), rabbit an i-human 
SULT2B1b, rabbit anti-rat STa (rSULT2A1), or mouse anti-rat STe (rSULT1E1). The 
primary antibodies were diluted to 1:1000 in TBST (50 mM Tris, pH 7.5, 150 mM NaCl, 
and 0.05% (v/v) Tween 20) containing 5% (w/v) nonfat dry milk. The membranes were 




membranes were washed 3 times with TBST for 15 min each wash and incubated in 
secondary antibody (horseradish peroxidase-conjugated Immuno-Pure goat anti-r bbit , 
rabbit anti-goat and rabbit anti-mouse IgG; H + L) at 1:5000 dilutions in TBST for a 
minimum of 1 h at room temperature. The membranes were then washed 3 times with 
TBST for 15 min each wash. Fluorescent bands were developed with 2 ml of substrate 
containing the same volume of each Super Signal West Pico Luminol Enhancer solution 
and Super Signal West Pico Stable Peroxidase solution at room temperature for 5 min. 
The fluorescence image was obtained from VersaDoc Imaging System 5000 (Bio-Rad, 
Hercules, CA). The densitometric quantification of protein bands was performed with 
Quantity One 4.6.5 software included with the VersaDoc imaging system. 
 
Quantitative Real-Time Polymerase Chain Reaction (qRT-PCR) 
 Total RNA was extracted from the liver, the thyroid gland, the adrenal gland and 
the testis/ovary cells using TRI REAGENT (Molecular Research Center, I c., Cincinnati, 
OH) according to the manufacturer's protocol. The concentration and purity of the 
extracted RNA were checked spectrophotometrically by measuring 260/280 absorption 
ratios. M-MLV Reverse Transcriptase (Promega, Madison, WI) with 1 µg of total RNA 
was used to synthesize cDNA, and 5 µl of reverse-transcribed product served as the 
template in polymerase chain reactions.  
 Real-time PCR was performed on a fluorescence temperature cycler (Applied 
Biosystems 7500 Real-Time PCR System) using the qPCR MasterMix Plus with SYBR® 




(Applied Biosystems, Foster City, CA). This system uses fluorescence-based PCR 
chemistries to provide quantitative detection of nucleic acid sequence using real-time 
analysis. Amplifications were carried out using 12.5 µl of 2×SYBR® Green PCR Master 
Mix, which contains SYBR® Green I dye, AmpliTaq® Gold DNA Polymerase, 
deoxynucleoside triphosphates with deoxyuricil triphosphate, Passive Reference and 
optimized buffer components (Applied Sysytems), 0.5 µl of each primer, 2 µl  of cDNA 
in a total volumn of 25 µl . Real-time PCR conditions were: activation of DNA 
polymerase at 95 ℃ for 10 min, followed by 40 cycles of melting at 95 ℃ for 15 sec and 
annealing and extension at 60 ℃ for 1 min. SYBR® Green I fluorescence was detected at 
the end of each cycle to monitor the amount of PCR product formed during the cycle. A 
dissociation curve analysis of the amplification products was performed at the end of the 
PCR run by rapidly increasing the temperature to 95 ℃ followed by immediate cooling to 
60 ℃ for 1 min, after which the temperature was gradually increased to 95 ℃ with 
continuous measurement of fluorescence to confirm amplification of specific trans ripts. 
The overall results obtained were analyzed by Applied Biosystems' 7500 System 
Sequence Detection Software Version 1.2.3 (Applied Biosystems, Foster City, CA).  
 Primers were designed with Primer Express Software (Applied Biosystems, 
Foster City, CA) as follows: rSULT2A1-F537: 5’-TCATGGTTTGAGCA TCCG-3’, 
rSULT2A1-R661: 5’-CTTGAGGGCCAAATCCAGCTCA-3’; rSULT2B1a-F214: 5'-
AGGAT CATCG TGGAA TGGAG-3', rSULT2B1a-R437: 5'-GGTCC CCATC TTTCA 
GGATT-3'; rSULT2B1b-F75: 5'-CTATG GGGCT CATTG GAGAA-3', rSULT2B1b-




 Rat β-actin was used to normalize rSULT2A1, rSULT2B1a, and rSULT2B1b 
mRNA levels, and the data was analyzed by relative quantification method. Primer
sequences for β-actin were: rβ-actin-F320: 5’-AGGCC CCTCT GAACC CTAAG-3’, r β-
actin-R435: 5’-AGAGG CATAC AGGGA CAACA CA-3’. Each sample was run in 
duplicate within a reverse transcription qRT-PCR experiment, and each experiment was 
repeated a minumun of three times.  
 
Data Analysis 
 One-way ANOVA followed by the Dunnett’s test was used to calculate the 
statistical significance of the difference between the control group means and 
methamphetamine treatment group means. In all cases, *, P<0.05 was considered 
significant; **, P<0.01 was considered very significant. Data presented in the figur s are 









RESULTS AND FINDINGS 
 
Distribution of rSULT2A1, rSULT1A1, and rSULT2B1b in the liver, the thyroid 
gland, the adrenal gland and the ovary of female rats 
 All of the rats used for distribution experiments were from the control group. 
Figure 1a shows the distribution of SULT2A1 in the liver, the thyroid gland, the adren l 
gland and the ovary of female rats. The results show that SULT2A1 is expressed in all 
four organs, but the expression levels vary varied among these four organs. The highest 
expression of rSULT2A1 occurs in the liver, which is 50 times more than the lowest 
expression, found in the thyroid gland.  In Figure 1b, one can see that SULT1E1 is 
expressed in each of the four organs, with highest expression in the liver. Figure 1c 
shows that SULT2B1b is expressed by all four of these organs with the highest 




Effects of methamphetamine treatment on rSULT2B1b in the thyroid gland of 
female and male rats 
 Figure 2 shows the effect of methamphetamine  on the expression of rSULT2B1b 
in the thyroid gland of female and male rats. In female rats, the highest dos of 
methamphetamine (20 mg/kg) increased the expression of rSULT2B1b significantly (2.5 
fold, P< 0.05). In male rats, the highest dose of methamphetamine (20 mg/kg) 
significantly induced the expression of rSULT2B1b (4 fold, p< 0.01). For both male and 
female rats, the two lower dose treatments (1 mg/kg and 5 mg/kg) didn't show significant 
effect on the expression of rSULT2B1b (p> 0.05). 
 
Effects of methamphetamine treatment on rSULT2B1b in the adrenal gland of 
female and male rats 
 Figure 3a shows the effect of methamphetamine  on the expression of 
rSULT2B1b in the adrenal gland of female and male rats. In female rats, the expression 
of rSULT2B1b was significantly induced by methamphetamine treatment in all three 
experimental groups (1.6 fold in 1 mg/kg group, p< 0.01; 1.7 fold in 5 mg/kg group, p< 
0.01; 1.4 fold in 20 mg/kg, p< 0.05). In male rats , only the lowest dose treatment (1 
mg/kg) induced the expression of rSULT2B1b significantly (1.7 fold, p< 0.05). The 
changes in rSULT2B1b expression in the other two highest-dose experimental groups 
were not statistically significant in males (p> 0.05). Reverse transcription qRT-PCR 




induced significantly (p< 0.05) by methamphetamine only in the lowest dose group (1 
mg/kg), while the other experimental groups were not significantly induced(p> 0.05).  
 
Effects of methamphetamine treatment on rSULT2B1b in the ovary of female rats
 Figure 4 shows the effects of methamphetamine on rSULT2B1b in the ovary of 
female rats. Higher doses of methamphetamine significantly induced the expression of 
rSULT2B1b (2.7 fold in 5 mg/kg group, p< 0.05; 2.6 fold in 20 mg/kg group, p< 0.01), 
while rSULT2B1b expression in the lowest dose group (1 mg/kg) was very similar to the 
expression in the control group.  
 
Effects of methamphetamine treatment on rSULT2B1a in the testis of male rats 
 Figure 5 shows the effects of methamphetamine on rSULT2B1a in the testis of 
male rats. As showed in Figure 5a, methamphetamine treatment significantly nduced the 
expression of rSULT2B1a in all three experimental groups (1.8 fold in 1 mg/kg group, p< 
0.05; 3 fold in 5 mg/kg group, p< 0.01; 3.5 fold in 20 mg/kg group p< 0.05). The result of 
reverse transcription qRT-PCR on the testis of rats (Figure 5b) shows that the lower doses 
of the drug treatment significantly induced mRNA transcription of rSULT2B1a in the 
testis of rats, while the highest dose group (20 mg/kg) did not change significantly after 






Effects of methamphetamine on rSULT2B1b in the liver of female and male rats 
 Figure 6a shows that higher doses of one day methamphetamine treatment 
significantly induced the expression of rSULT2B1b in the liver of female rats (3.7 fold in 
5 mg/kg group, p< 0.01; 2.4 fold in 20 mg/kg group, p< 0.05), while the lowest dose 
group (1 mg/kg) showed no significant induction. In the liver of male rats , there was no 
significant change of the expression of rSULT2B1b after the drug treatment between 
each experimental group and the control group. However, the reverse transcription qRT-
PCR results in the liver of male rats (Figure 6b) showed a marked inhibition of 
rSULT2B1b mRNA transcription in 1 mg/kg group (40%, p< 0.01) and 20 mg/kg group 
(60%, p< 0.01). 
 
Effects of methamphetamine on rSULT2A1 in the liver of male and female rats 
 Figure 7a shows that the expression of rSULT2A1 in each of the three 
experimental groups did not change significantly (p> 0.05) in the liver of female rats after 
one day methamphetamine treatment. In the mean time, reverse transcription qRT-PCR 
result in Figure 7b shows that the mRNA transcription of rSULT2A1 in the liver of 
female rats was not affected by one day methamphetamine treatment as well. In male rats 
(Figure 7a), higher doses of methamphetamine treatment significantly inhibited the 
expression of rSULT2A1 (50% in 5 mg/kg group, p< 0.05; 60% in 20 mg/kg group, p< 
0.05), while the lowest dose treatment of methamphetamine (1 mg/kg) did not 





Effects of methamphetamine on rSULT2A1 in the ovary of female rats and the testis 
of male rats 
 Figure 8a shows that higher doses of one day methamphetamine treatment 
significantly induced the expression of rSULT2A1 in the ovary of female rats (2 fold in 5 
mg/kg group, p< 0.05; 3.1 fold in 20 mg/kg group, p< 0.01), while the lowest dose group 
of drug treatment (1 mg/kg) did not change the expression of rSULT2A1 significantly. 
Figure 8b shows that the expression of rSULT2A1 in the testis of male rats was not 
affected by one day treatment of methamphetamine. 
 
 Effects of methamphetamine on rSULT1A1 in the liver, the thyroid gland, and the 
ovary of female rats 
 In Figure 9a, western blotting results demonstrate that higher doses of one day 
methamphetamine treatment significantly increased the expression of rSULT1A1 in the 
thyroid gland of female rats (6.5 fold in 5 mg/kg, p< 0.05; 5 fold in 20 mg/kg, p< 0.05). 
Figure 9b shows that the expression of rSULT1A1 in the ovary of female rats did not 
change significantly after the drug treatments. Surprisingly, the expression of rSULT1A1 
in the liver of female rats (Figure 9c) was decreased significantly due to 
methamphetamine treatment (80% in 1 mg/kg group, p< 0.01; 80% in 20 mg/kg, p< 






Effects of methamphetamine on the expression of rSULT1E1 in the ovary of female 
rats 
 The expression of rSULT1E1 in the ovary of female rats was not significantly 









Figure 1. Distribution of sulfotransferase isoform 2A1 (Figure 1a), 1E1 (Figure 1b), and 
2B1b (Figure 1c) in the liver, the adrenal gland, the ovary, and the thyroid glan of 
female rats.  
 The densitometric quantification of protein bands was performed with Quantity 
One 4.6.5 software of the Bio-Rad VersaDoc imaging system. Each western blotting 
experiment was repeated at least three times and the data presented ar m ans ± S.D. of 
the data collected separately from at least three independent animals. 
Figure 2. Expression change of sulfotransferase 2B1b 24 hours after a single dose 
treatment of methamphetamine in the thyroid gland of female and male rats.  
 The densitometric quantification of protein bands was performed with Quantity 
One 4.6.5 software of the Bio-Rad VersaDoc imaging system. Each western blotting 
experiment was repeated at least three times and the ata presented are means ± S.D. of 
the data collected separately from at least three independent animals. * P<0.05 compared 




Figure 3. Expression change of sulfotransferase 2B1b 24 hours after a single dose 
treatment of methamphetamine in the adrenal gland of female and male rats (Figure 3a). 
mRNA transcription change of sulfotransferase 2B1b after 1 day treatment of 
methamphetamine in the adrenal gland of male rats (Figure 3b). 
 The densitometric quantification of protein bands was performed with Quantity 
One 4.6.5 software of the Bio-Rad VersaDoc imaging system. Each western blotting 
experiment was repeated at least three times and the ata presented are means ± S.D. of 
the data collected separately from at least three independent animals. * P<0.05 compared 
to control group; ** P<0.01 compared to control group. Real time RT-PCR results were 
analyzed by the 7500 System Sequence Detection Software Version 1.2.3 (Applied 
Biosystems, Foster City, CA). Each sample was run in duplicate within a reverse 
transcription qRT-PCR experiment, and each experiment was repeated a minumun of 
three times. The data presented are means ± S.D. of the data collected separately from at 
least three independent animals. * P<0.05 comparing with the control group; ** P<0.01 
comparing with the control group. 
Figure 4. Expression change of sulfotransferase 2B1b 24 hours after a single dose 
treatment of methamphetamine in the ovary of female rats. 
 The densitometric quantification of protein bands was performed with Quantity 
One 4.6.5 software of the Bio-Rad VersaDoc imaging system. Each western blotting 
experiment was repeated at least three times and the ata presented are means ± S.D. of 
the data collected separately from at least three independent animals. * P<0.05 compared 




Figure 5. Expression change of sulfotransferase 2B1a 24 hours after a single dose 
treatment of methamphetamine in the testis of male rats (Figure 5a). mRNA transcription 
change of sulfotransferase 2B1a 24 hours after a single dose treatment of 
methamphetamine in the testis of male rats (Figure 5b). 
 The densitometric quantification of protein bands was performed with Quantity 
One 4.6.5 software of the Bio-Rad VersaDoc imaging system. Each western blotting 
experiment was repeated at least three times and the ata presented are means ± S.D. of 
the data collected separately from at least three independent animals. * P<0.05 compared 
to control group; ** P<0.01 compared to control group. reverse transcription qRT-PCR 
results were analyzed by the 7500 System Sequence Detection Software Version 1.2.3 
(Applied Biosystems, Foster City, CA). Each sample were run at least three duplications 
and the data presented are means ± S.D. of the data collected separately from at least 
three independent animals. * P<0.05 comparing with the control group; ** P<0.01 
comparing with the control group. 
Figure 6. Expression change of sulfotransferase 2B1b 24 hours after a single dose 
treatment of methamphetamine in the liver of female and male rats (Figure 6a). mRNA 
transcription change of sulfotransferase 2B1b 24 hours after a single dose treatment of 
methamphetamine in the liver of male rats (Figure 6b). 
 The densitometric quantification of protein bands was performed with Quantity 
One 4.6.5 software of the Bio-Rad VersaDoc imaging system. Each western blotting 
experiment was repeated at least three times and the ata presented are means ± S.D. of 




to control group; ** P<0.01 compared to control group. reverse transcription qRT-PCR 
results were analyzed by the 7500 System Sequence Detection Software Version 1.2.3 
(Applied Biosystems, Foster City, CA). Each sample were run at least three duplications 
and the data presented are means ± S.D. of the data collected separately from at least 
three independent animals. * P<0.05 comparing with the control group; ** P<0.01 
comparing with the control group. 
Figure 7. Expression change of sulfotransferase 2A1 24 hours after a single dose 
treatment of methamphetamine in the liver of female and male rats (Figure 7a). mRNA 
transcription change of sulfotransferase 2A1 24 hours after a single dose treatment of 
methamphetamine in the liver of female rats (Figure 7b). 
 The densitometric quantification of protein bands was performed with Quantity 
One 4.6.5 software of the Bio-Rad VersaDoc imaging system. Each western blotting 
experiment was repeated at least three times and the ata presented are means ± S.D. of 
the data collected separately from at least three independent animals. * P<0.05 compared 
to control group; ** P<0.01 compared to control group. reverse transcription qRT-PCR 
results were analyzed by the 7500 System Sequence Detection Software Version 1.2.3 
(Applied Biosystems, Foster City, CA). Each sample was run in duplicate within a 
reverse transcription qRT-PCR experiment, and each experiment was repeated a 
minumun of three times. The data presented are means ± S.D. of the data collected 
separately from at least three independent animals. * P<0.05 comparing with the control 




Figure 8. Expression change of sulfotransferase 2A1 24 hours after a single dose 
treatment of methamphetamine in the ovary of female rats (Figure 8a) and the testis of 
male rats (Figure 8b).  
 The densitometric quantification of protein bands was performed with Quantity 
One 4.6.5 software of the Bio-Rad VersaDoc imaging system. Each western blotting 
experiment was repeated at least three times and the ata presented are means ± S.D. of 
the data collected separately from at least three independent animals. * P<0.05 compared 
to control group; ** P<0.01 compared to control group.  
Figure 9. Expression change of sulfotransferase 1A1 24 hours after a single dose 
treatment of methamphetamine in the thyroid gland (Figure 9a), the ovary (Figure 9b), 
and the liver (Figure 9c) of female rats.  
 The densitometric quantification of protein bands was performed with Quantity 
One 4.6.5 software of the Bio-Rad VersaDoc imaging system. Each western blotting 
experiment was repeated at least three times and the ata presented are means ± S.D. of 
the data collected separately from at least three independent animals. * P<0.05 compared 
to control group; ** P<0.01 compared to control group.  
Figure 10. Expression change of sulfotransferase 1E1 24 hours after a single dose 
treatment of methamphetamine in the ovary of female rats.  
 The densitometric quantification of protein bands was performed with Quantity 
One 4.6.5 software of the Bio-Rad VersaDoc imaging system. Each western blotting 




the data collected separately from at least three independent animals. * P<0.05 compared 
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 Methamphetamine affects hormonal secretions of the thyroid gland, the adrenal 
gland and the testis/ovary either by directly interacting with specific receptors on the cell 
surface or indirectly through the increase of dopamine level in the nervous system (Melis 
& Argiolas, 1995; Agmo & Fernandez, 1989; Giuliano & Allard, 2001; Power, Mani, 
Codina, Conneely, & O'Malley, 1991; Sprague et al., 2003; Grace et al., 2010; Williams 
et al., 2006; Williams et al., 2000; Schaefer et al., 2008). The phase II drug-metabolizing 
enzyme cytosolic sulfotransferases (SULTs) have been shown to be involved in 
regulating the activities of these endogenous hormones in the existence of sulfatases 
(Luu-The et al., 1996; Chapman et al., 2004).  Some steroid hormones are the targets of 
cytosolic sulfotransferases (Luu-The et al., 1996; Chapman et al., 2004). However, the 
information regarding the effects of METH on the expression of SULTs in these
endocrine glands is very limited. In the present study, we investigated protein expression 
and mRNA transcription changes of selected SULT isoforms (rSULT1A1, rSULT1E1, 




of female and male Sprague-Dawley rats  24 hours after acute methamphetamine 
exposure. We also investigated the effects of METH on those SULT isoforms in the l ver 
of female and male rats in the same treatment. Because the liver is the main 
detoxification organ in the body and is one of the targeting tissues of endocrine 
hormones, we were interested in studying the effects of METH on SULTs in the liver.  
 The data show that the cholesterol sulfotransferase, rSULT2B1b, expression wa  
significantly induced 24 hours after a single dose treatment of METH in all of the three 
endocrine glands studied in female rats. rSULT2B1b expression in the thyroid gland and 
the adrenal gland of male rats was also significantly induced by METH. According to 
Kohjitani et al. (Kohjitani, Fuda, Hanyu, &Strott, 2005) and our experimental results, 
rSULT2B1a is the only SULT2B isoform expressed in the testis of rats. These results 
show that the expression of rSULT2B1a was induced significantly in the testis by one 
day METH treatment. The reverse transcription qRT-PCR results of rSULT2B1b and 
rSULT2B1a agreed with Western blotting data in the adrenal gland and the tes is of male 
rats (We failed to save enough samples of female rats for reverse tran cription qRT-
PCR). This suggests that the regulation of rSULT2B1a and rSULT2B1b by METH in the 
adrenal gland and the testis of male rats might occur at the transcriptional level. The 
expression of rSULT2A1 was shown by Western blotting to be significantly induced in 
the ovary of female rats after the METH treatment. The expression of rSULT2A1 was 
inhibited in the liver of male rats by METH. rSULT2A1 expression was not changed 
significantly in the testis of male rats or in the liver of female rats. mRNA transcription of 
rSULT2A1 in the liver of female rats also did not change significantly after the drug 




male rats after the drug treatment. Surprisingly, rSULT1A1 was inhibited s gnificantly in 
the liver of female rats by METH according to our Western blotting results. The 
expression of rSULT1A1 in the ovary of female rats was not affected by METH. For 
rSULT1E1, we only got results in the ovary of female rats by Western blotting, and the 
expression of this enzyme in the ovary was not affected by METH treatment. 
 The effects of methamphetamine on endocrine hormones have been studied in the 
past few years. METH exposure increased both instant and chronic release of 
corticosteroids in human (Grace et al., 2010; Williams et al., 2006; Williams et al., 2000; 
Schaefer et al., 2008). It has also been reported that thyroxine (T4) level had been 
significantly induced after a single high dose treatment (40 mg/kg) of a 
methamphetamine derivative MAMA (3,4-methylenedioxymethamphetamine) (Sprague 
et al., 2003). METH exposure significantly increases dopamine levels in the synapse by 
blocking dopamine reuptake by the neuron cells (Brennan et l., 2010; Melo et al., 2010). 
The female sex hormones, estrogens, are reported to be able to diminish the amount of 
striatal dopamine depletion caused by METH exposure (Dluzen & McDermott, 2002). 
The sex-dependent estrogen level might be the reason for the different METH-induced 
neurotoxicity in male and female individuals (Yu & Liao, 2000). According to our 
experimental results (Figures 2, 3, and 4), the expression levels of rSULT2B1b in these 
three endocrine glands were induced significantly by a single dose 24 hours 
methamphetamine treatment  in both female and male rats. In the testis, rSULT2B1a 
expression was also significantly induced by METH in the same treatment.  
 Though the primary antibody we used in the testis was the same primary antibody 




testis from this antibody was rSULT2B1a. First, because the sequences of rSULT2B1a 
and rSULT2B1b are 99% identical, the antibody that recognizes rSULT2B1b should also 
recognize rSULT2B1a, and the band obtained was approximately 41 KDa, which is the 
molecular weight for rSULT2B1a. Secondly, we could not get a rSULT2B1b 
amplification product using either reverse transcription qRT-PCR or traditional reverse 
transcription PCR, while rSULT2B1a could be amplified with reverse transcription qRT-
PCR. Finally, Kohjitani et al. also failed to amplify rSULT2B1b in the testis of male rats 
(Kohjitani et al., 2006). rSULT2B1a is specific for sulfation of pregnenolone, which is 
the precursor of testosterone and estrogens. SULT2B1b is also known as the cholesterol 
sulfotransferase, specifically catalyzing the sulfation of cholesterol as well as most 
cholesterol derivatives (Fuda et al., 2007). SULT2B1b has been reported not to directly 
participate in detoxification of xenobiotics but to regulate the signaling pathway of 
endogenous hormones signaling pathway (Chen et al., 2007; Glass & Saijo, 2008; Fuda 
et al., 2007). Chen et al. reported that overexpression of rSULT2B1b would attenuate the 
liver X receptors (LXRs) signaling in cultured mammalian cell lines by adding the 
sulfuryl groups to the oxysterol LXR ligands (Chen et al., 2007). LXRs are nuclear 
receptors regulating the fatty acid and cholesterol metabolism in vivo complementarily 
with another nuclear receptor sterol regulatory element binding protein (SREBP) (Glass 
& Saijo, 2008). SREBP independently controls the cholesterol synthesis and uptake, 
while LXRs are activated by binding with oxysterol ligands to bind and promote the 
transcription of genes limiting the amount of cholesterol in the cell (Glass & Saijo, 2008). 
Oxysterols are the newly-found specific substrate for SULT2B1b (Chen et al., 2007). 




the transcription of the genes limiting cholesterol synthesis and uptake. These will trigger 
the subsequent cholesterol accumulation and lipid metabolizing pathway (Glass & Saijo, 
2008).   
 The adrenal cortex synthesizes adrenal steroid hormones (corticosteroids), that 
regulate salt and water balance in the body, response to stresses, and are also involved in 
the immune system, and sexual development and function of the body (Maggio & Segal, 
2010). Steroid hormones are derived from the same precursor, cholesterol, through a 
complex series of biochemical reactions (Hardy & Cooper, 2010). The significant 
induction of rSULT2B1b expression in the adrenal gland after METH treatment shown 
by our results (Figure 3) may contribute to the long term increase in the adrenal hormone 
production. Under normal physiological conditions, LXRs work with SREBP 
complementarily to maintain the cholesterol level in the cell. When rSULT2B1b 
expression is induced by METH, the enzyme will sulfate the free oxysterols in the cell 
and make it unable to bind with LXRs. The inactive LXRs cannot bind and promote the 
transcription of the genes limiting the amount of cholesterol in the cell, resulting in the 
accumulation of cholesterol in the adrenal gland cells. Since cholesterol is the precurso  
of all steroid hormones synthesized by the adrenal gland, the accumulation of cholesterol 
in the adrenal cortex may contribute to the increased production of steroid hormones after 
METH treatment. On the other hand, the rapid release of adrenal hormones after METH 
exposure may result from another pathway which is downstream of the binding of METH
to the dopamine receptors on the surface of the adrenal gland cells. The instantly 
increased adrenal hormones may play a role in the induction of rSULT2B1b expression, 




through the pathway we discussed above. It is clear that defining the mechanism of 
rSULT2B1b induction will help better understand the whole METH regulating pathway. 
The mechanism of rSULT2B1b induction after METH treatment in the adrenal cortex is 
being investigated in our lab now. We strongly believe that rSULT2B1b is involved in 
the induced secretion process of steroid hormones in the adrenal cortex. 
 LXRs also play an important role in regulating lipid metabolism and thyroid 
hormone status. Synthetic LXR agonist has been reported to significantly decrease th  
thyronine/thyroxine (T3/T4) ratio in plasma (Davies et al., 2008). And this decrease 
happened together with the decreased expression of deiodinase 1 (DIO1) and 2(DIO2) 
mRNA in the thyroid gland (Davies et al., 2008). In addition, expression of SREBP-1c 
was markedly increased in the thyroid gland (Davies et al., 2008). These demonstrated 
that T4 production was actually increased after deactivating LXRs by using the LXR 
agonist. Our results show that rSULT2B1b expression was significantly induced by high 
dose METH injection (20 mg/kg). The induced expression of rSULT2B1b will sulfate 
oxysterols and prevent them from binding with LXRs, and that will make LXRs inactive. 
We believe the LXRs deactivated through the pathway we proposed will have the same 
effect of the inactive LXRs deactivated by synthetic LXR agonist, that is, increasing T4 
production in the thyroid gland. The increased T4 level is the effect that Sprague et al. 
monitored after a single high dose treatment of a methamphetamine (40 mg/kg)
derivative MAMA (3,4-methylenedioxymethamphetamine) (Sprague et al., 2003). Thus, 
we believed that rSULT2B1b is involved in the increase of T4 production in the thyroid 




 Estrogens are synthesized in the ovary from the precursor cholesterol. Estrogen is 
reported to diminish the amount of striatal dopamine depletion by METH (Dluzen & 
McDermott, 2002). They are present in significantly higher level in women than in men. 
The sex-dependent expression of estrogen has been reported to be the reason for the 
sexual differences of METH-induced striatal neurotoxicity (Yu & Liao, 2000). METH 
can induce more serious neurotoxicity in men than in women (Yu & Liao, 2000). 
Furthermore, ovariectomized female rats were less likely to abuse METH when allowed 
free-choice access to the drug, as determined by decreased intake of METH (Kucerova, 
Vrskova, & Sulcova, 2009). These all indicate that constantly expressed estrogen can 
reduce the dopamine depletion after METH treatment and decrease the neurotoxicity 
induced by METH. Our results show that the expression of rSULT2B1b was induced by 
METH in the ovary of female rats. The increased rSULT2B1b enzyme may cause an 
accumulation of cholesterol in the ovary cells through the pathway discussed above in the 
adrenal and thyroid gland paragraph. Since cholesterol is also the precursor of all three 
estrogens, the increased cholesterol level may result in more estrogen synthesi  which 
will further protect the neuron cells from METH's neurotoxic effects. In the testis, 
estrogens are produced far less in levels than those produced in the ovary. In addition, 
according to our experimental results, protein expression and mRNA transcription of 
rSULT2B1a were both induced in testis of rats. rSULT2B1a is specific for sulfation of 
pregnenolone, which is the precursor of estrogens and testosterone. This will further 
decrease the amount of estrogens in male rats. Furthermore, testosterone i also reported 
to counteract the neurotoxicity of METH similar to estrogen (Dluzen & McDermott, 




will intensify the neurotoxicity caused by METH treatment. These may answer why 
female individuals are reported to exhibit less neurotoxic effects resulting from METH 
than males. The induction of both protein expression and mRNA transcription of 
rSULT2B1a suggests that the induction of rSULT2B1a by METH may occur on the 
transcriptional level. The mechanism of the induction of rSULT2B1b and rSULT2B1a in 
the ovary and the testis is under investigation in our lab now. We believe the mechanism 
of rSULT2B1b and rSULT2B1a induction in the ovary and the testis is involved in the 
sex-dependent neurotoxicity in female and male individuals.  
 The expression changes of other SULT isoforms are not consistent throughout the 
three endocrine glands studied, suggesting that the roles other SULT isoforms play in 
those glands vary from tissue to tissue. Since SULT2A1 is responsible for the sulfation o  
hydroxysteroids and may be involved in eliminating excess hormones from the body 
(Pacifici, 2005), it is more likely to have increased expression in those endocrine glands 
and decreased expression in the hormone target organs, such as kidney and liver. Our 
results show that the expression of rSULT2A1 was increased in the ovary of female rats. 
However, the expression of rSULT2A1 has been significantly inhibited by METH in the 
liver of male rats while not significantly changed in the liver of female rts. This different 
regulation of rSULT2A1 by METH may result from the mediation of certain nuclear 
receptors (Chen et al. 2006; Fang et al. 2007; Kin et al. 2004; Seely et al. 2005). In 
ovary, METH may induce the expression of rSULT2A1 by binding to certain nuclear 
receptors. And in liver, METH may inhibit the expression of rSULT2A1 through 
endogenous hormones that competitively bind to nuclear receptors. Further studies are 




unveiling of these mechanisms will uncover the mystery of how METH works to change 






SUMMARY AND CONCLUSIONS 
 In present study, we have investigated the comparative levels of different SULT 
isoforms and the effects of methamphetamine on sulfotransferases in the endocrine 
glands and the liver of rats. The results can be summarized as follows: 
1. Distribution experiments showed that rSULT1E1, rSULT2B1b, and rSULT2A1 
are expressed in the thyroid gland, the adrenal gland, the ovary and the liver of 
female rats. 
2. The highest dosage of METH (20 mg/kg) significantly induced the expression of 
rSULT2B1b in the thyroid gland of both female and male rats. 
3. METH significantly induced the expression of rSULT2B1b in the adrenal gland 
of female rats. 
4. The lowest dosage of METH (1 mg/kg) significantly induced the mRNA 
transcription and protein expression of rSULT2B1b in the adrenal gland of male 
rats. This indicates that the regulation of rSULT2B1b in the adrenal gland of male 




5. METH (5 and 20 mg/kg) significantly induced the expression of rSULT2B1b in 
the ovary of female rats. 
6. METH significantly induced the mRNA transcription and the protein expression 
of rSULT2B1a in the testis of male rats. This indicates that the regulation of 
rSULT2B1a in the testis of male rats may occur on the transcriptional level. 
7. METH (5 and 20 mg/kg) significantly induced the expression of rSULT2B1b in 
the liver of female rats. 
8. 5 mg/kg and 20 mg/kg treatment of METH significantly inhibits the expression of 
rSULT2A1 in the liver of male rats. 
9. 5 mg/kg and 20 mg/kg treatment of METH significantly induces the expression of 
rSULT2A1 in the ovary of female rats. 
10. 5 mg/kg and 20 mg/kg treatment of METH significantly induces the expression of 
rSULT1A1 in the thyroid gland of female rats. 
11. METH significantly inhibits the expression of rSULT1A1 in the liver of male 
rats. 
 
 In summary, METH significantly induced the expressions of rSULT2B1b in the 
thyroid gland and the adrenal gland of both female and male rats. This suggests that 
rSULT2B1b may be responsible for the increase of thyroid and adrenal hormone 
productions after METH exposure through the LXR regulating signaling pathway, 
because rSULT2B1b is strongly related to the activation and deactivation of LXRs. 
METH also significantly induced the expression of rSULT2B1b in the ovary and the 




rSULT2B1a may be involved in the expression change of estrogens and testosterone in 
the ovary and testis of rats caused by METH treatment. Sex-dependent sex hormone 
levels may serve as one of the reasons for the different METH-induced neurotoxicity in 
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Scope and Method of Study: My objectives were to: 1) To investigate the effects o  
METH on protein expression of different SULT isoforms in the adrenal gland, the 
thyroid gland, and the ovary/testis of rats. 2) To investigate the effects of METH 
on mRNA transcriptions of different SULT isoforms in the adrenal gland, the 
thyroid gland, and the ovary/testis of rats. 3) To investigate the effects of METH 
on protein expression and mRNA transcription of SULTs in the liver of rats. Male 
and Female Sprague-Dawley rats (Harlan, Indianapolis, IN), 10 to 11 weeks old 
and 200-300 g body weight were used in this investigation. Rats were housed in a 
temperature- and humidity-controlled room and supplied with rodent chow and 
water for at least 1 week before use. Rats were divided randomly into groups of 
four. Methamphetamine was dissolved in saline and administrated by 
intraperitoneal injection at 1, 5 and 20 mg/kg to 3 separate groups of rats. The 
control rats received only the saline vehicle. The treatment was single dose 
treatment. The rats were euthanized 24 h after the drug treatment. The livers, the 
thyroid gland, the adrenal glands, and the testes/ovaries were collected from each 
rat and were snap-frozen in liquid nitrogen. Samples were stored at -80 ℃ until 
use. 
 
Findings and Conclusions: I found that METH significantly induced the expressions of 
the rat cholesterol sulfotransferase (rSULT2B1b) in the thyroid gland and the 
adrenal gland of both female and male rats. This suggests that rSULT2B1b may 
play a role in the increase of thyroid and adrenal hormone productions after 
METH exposure through the Liver X Receptor (LXR) regulating pathway, 
because rSULT2B1b is strongly related to the activation and deactivation of 
LXRs. I also found that METH significantly induced the expression of 
rSULT2B1b in the ovary and the expression of the rat pregnenolone 
sulfotransferase (rSLUT2B1a) in the testis of rats. This suggests that rSULT2B1b 
and rSULT2B1a may be involved in the expression change of estrogens and 
testosterone in the ovary and testis of rats caused by METH treatment. Sex-
dependent sex hormone levels may serve as one of the reasons for the different 
METH-induced neurotoxicity in female and male individuals.  
